News
JNJ
--
0.00%
--
Cramer on how J&J's stock has performed in relation to vaccine news
A key Food and Drug Administration advisory panel will review and vote on Johnson & Johnson’s single-shot Covid-19 vaccine on Friday, potentially paving the way for an emergency use authorization in the coming days. CNBC's Jim Cramer and David Faber discus...
CNBC.com · 1h ago
The Great Promise of a One-Dose Vaccine
Look past the confusing efficacy reports about J&J's vaccine candidate. The shot promises to speed up vaccination everywhere.
Barrons.com · 1h ago
FDA Panel To Discuss J&J's Covid Vaccine: What You Need To Know
A committee of medical experts will meet Friday to discuss Johnson & Johnson's Covid vaccine. The results could spark JNJ stock.
Investor's Business Daily · 1h ago
5 things to know before the stock market opens Friday
U.S. stock futures were choppy as tech stocks bounced from Thursday's rout that dragged the Nasdaq down 3.5%
CNBC.com · 1h ago
An FDA Committee Meets Today to Discuss Johnson & Johnsons Vaccine. Heres What to Expect.
The FDA would likely move very rapidly to issue an emergency use authorization of the vaccine once approved.
Barrons.com · 2h ago
UPDATE 2-Canada approves AstraZeneca's COVID-19 shot in boost to vaccination push
reuters.com · 2h ago
UPDATE 1-Canada approves AstraZeneca's COVID-19 vaccine
reuters.com · 2h ago
Canada approves AstraZeneca's COVID-19 vaccine
reuters.com · 2h ago
The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25)
Benzinga · 2h ago
What's Moving The Market Friday? US Stocks Near Flat, Euro, Asian Stocks Lower
Indices Around The Globe S&P 500 Futures about flat, rebounded off 3,801.5 pre-market low UK's FTSE 100 down 1.4% Japan's Nikkei 225 down 4% Bonds 10-year treasury yield at 1.518% Commodities
Benzinga · 3h ago
Novavax Surges Again On Vaccine Supply Deal; Is NVAX Stock A Buy?
Novavax is making a play for a coronavirus vaccine, vs. giants like Pfizer, and rivals like Moderna. But NVAX stock has been volatile. Is Novavax a buy?
Investor's Business Daily · 3h ago
Johnson & Johnson's COVID-19 Vaccine Likely To Get EU Approval Early March: Bloomberg
Benzinga · 3h ago
J&J’s COVID-19 vaccine set to undergo FDA review; EU review set for early March
An FDA expert panel is scheduled to review the single-dose COVID-19 vaccine candidate from Johnson & Johnson (JNJ) today.An FDA authorization could soon follow subject to an endorsement. Even though the regulator
Seekingalpha · 3h ago
BRIEF-Sanofi to produce 27 mln COVID-19 vaccine doses/month from Sept -French minister
reuters.com · 4h ago
Coronavirus tally: Global cases of COVID-19 top 113 million and U.S. death toll atop 508,000
The global tally for confirmed cases of the coronavirus that causes COVID-19 climbed above 113 million on Friday, according to data aggregated by Johns...
MarketWatch · 4h ago
J&J COVID-19 vaccine set to get EU nod in early March - Bloomberg News
The European Union's medicines regulator is expected to recommend drugmaker Johnson & Johnson's COVID-19 vaccine on March 11, Bloomberg News reported https://bloom.bg/3stLMZR on Friday, a move that could give the region its fourth coronavirus vaccine.
Reuters · 4h ago
FDA advisory panel to review Johnson & Johnson COVID-19 vaccine with thumbs up expected
A panel of expert advisers to the U.S. Food and Drug Administration is expected to recommend authorization of a one-dose COVID-19 vaccine from Johnson & Johnson on Friday, setting the stage for the unleashing of millions more doses across the country next ...
Reuters · 4h ago
BRIEF-EMA Is Expected To Give J&J COVID-19 Shot Nod On March 11 - Bloomberg News
reuters.com · 4h ago
Johnson & Johnson Covid-19 Vaccine Said to Get EU Approval in Early March
-Bloomberg https://www.bloomberg.com/news/articles/2021-02-26/j-j-shot-set-to-get-eu-nod-in-early-march-easing-supply-squeeze
Bloomberg · 5h ago
5 things to know before key FDA panel votes on J&J's single-shot Covid vaccine today
A key FDA panel is to vote on whether to recommend J&J's Covid vaccine for emergency use, which would help pave the way for a third vaccine in the U.S.
CNBC.com · 5h ago
Webull provides a variety of real-time JNJ stock news. You can receive the latest news about Johnson&Johnson through multiple platforms. This information may help you make smarter investment decisions.
About JNJ
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.